1. CoNCERT’s Leading Portfolio Asset to step into GSK Paroxetine’s $3Bn Shoes
CoNCERT’s CTP-347 is a Phase 1 treatment for hot flashes that acts as a substitute for GSK’s Paroxetine, with the potential added benefit of little to no drug-drug interaction. Roger Tung and Eric Schmidt discuss future studies vs. Paroxetine or placebo. They also review CTP-518, an HIV protease inhibitor that could offer higher tolerability without a combination use with Ritonavir / Norvir (Abbott), simplifying drug use, and reducing cost to payors.
2. CoNCERT’s IPO, Partnering Strategies and Full Integration for it’s Deuterium Substitution Platform & Pipeline Assets
The applicability of CoNCERT’s pipeline extends beyond what it can accomplish as a small biotech. To what extent is CoNCERT willing to partner its platform and assets? Is full integration a future possibility? As Eric Schmidt interviews Roger Tung, he asks him about taking the company public. Roger and Eric also discuss the use of this platform beyond the current focus in what could a number of spin-outs. Finally, they take a look at the how CoNCERT’s technology can help drugs going off patent, and their parent companies that may be staring at the abyss.
3. CoNCERT’s Deuterium Substitution Platform to Create Better, Faster, Cheaper Drugs
Deuterium has the same properties as hydrogen, only it has the power to make molecules more stable. This creates a number of interesting applications for existing drugs. CoNCERT has developed a technological platform that substitutes hydrogen for deuterium, and has applied this process to a number of marketed drugs in the hopes of creating first or best in class drugs. Roger Tung, CEO of CoNCERT is interviewed by Eric Schmidt, Senior Biotech Analyst at Cowen on the properties of the modified drugs, and their patentability. Eric continues to ask Roger about the efficiency drug delivery process and it’s starting points. Finally Roger answers questions regarding CoNCERT’s cash position, and potential for growth.
This interview was conducted at the NASDAQ Marketsite, on November 3rd, 2008, in New York City.
Featuring:
DISCLAIMER: VIEWERS SHOULD VERIFY ALL CLAIMS AND DO THEIR OWN DUE DILIGENCE BEFORE INVESTING IN ANY SECURITIES MENTIONED. INVESTING IN SECURITIES IS SPECULATIVE AND CARRIES A HIGH DEGREE OF RISK.